ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1735

Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation

Takehiro Nakai1, Futoshi Iwata1, Genki Kidoguchi1, Sho Fukui2, Hiroki Ozawa1, Satoshi Kawaai3, Yukihiko Ikeda1, Ayako Koido4, Masei Suda5, Atsushi Nomura6, Hiromichi Tamaki1, Kenichi YAMAGUCHI1 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Immuno-Rheumatology Center, St. Luke’s International Hospital, and Center for clinical epidemiology, St. Luke’s International University, Tokyo, Japan, 3Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, Chuo-ku, Tokyo, Japan, 4St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan, 5Suwa Central Hospital, Nagano, Japan, 6St. Luke's International Hospital, Nagareyama, Japan

Meeting: ACR Convergence 2021

Keywords: ,

Session Information

Date: Tuesday, November 9, 2021

Session Title: SLE – Treatment Poster (1732–1772)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the risk factors for disease flares and flare rates with gradual glucocorticoid tapering, especially in patients with prior severe organ manifestation.

Methods: Patients with SLE who had their glucocorticoid doses tapered off at our institute were retrospectively analyzed. We divided the patients according to the presence of prior severe organ manifestations and compared the 52-week flare rates after glucocorticoid discontinuation. Furthermore, risks/protective factors against flares after glucocorticoid cessation were investigated.

Results: In total, 309 patients with SLE were followed up; 298 had prednisolone tapered to less than 7.5 mg/day and 75 had glucocorticoids discontinued. Seventy-three patients met the inclusion criteria; 49 were classified as SLE with prior severe organ manifestation. No statistical differences were noted in the 52-week flare rate and time to first flare after glucocorticoid discontinuation between patients with and without prior severe organ manifestation (52-week flare rate: 16.7% vs. 18.2%, p=1.0; time to first flare: 322 [280, 1169] vs. 385 [304, 2345] days, p=0.33). A positive anti-Smith/anti-ribonucleoprotein antibody negatively influenced flare-free remission. Although this result was not statistically significant, the achievement of lupus low disease activity state (LLDAS) on the day of glucocorticoid discontinuation positively influenced flare-free remissions after glucocorticoid discontinuation.

Conclusion: Glucocorticoid discontinuation can be achieved in patients with SLE with prior severe organ manifestations. Achievement of LLADS is key for reaching flare-free remission after glucocorticoid discontinuation.

Kaplan-Meier curve for flare free remission rate after glucocorticoid discontinuation

Risk factors for flares after glucocorticoid discontinuation

Disclosures: T. Nakai, None; F. Iwata, None; G. Kidoguchi, None; S. Fukui, None; H. Ozawa, None; S. Kawaai, None; Y. Ikeda, None; A. Koido, None; M. Suda, None; A. Nomura, None; H. Tamaki, None; K. YAMAGUCHI, None; M. Okada, Eli Lilly and Company, 6, Santen Pharmaceutical, 6, Mitsubishi Tanabe Pharma, 6, Pfizer, 6, Abbott Japan, 6.

To cite this abstract in AMA style:

Nakai T, Iwata F, Kidoguchi G, Fukui S, Ozawa H, Kawaai S, Ikeda Y, Koido A, Suda M, Nomura A, Tamaki H, YAMAGUCHI K, Okada M. Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/glucocorticoid-discontinuation-in-patients-with-systemic-lupus-erythematosus-with-prior-severe-organ-manifestation/. Accessed August 12, 2022.

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/glucocorticoid-discontinuation-in-patients-with-systemic-lupus-erythematosus-with-prior-severe-organ-manifestation/